ArticleCureus2026
Unanticipated Testicular Involvement in Prostate Carcinoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate carcinoma commonly metastasizes to distant organs; however, testicular involvement is exceedingly rare and may be overlooked in routine clinical practice. We report the case of a 78-year-old man with high-grade prostate adenocarcinoma who presented with a three-month history of painless hematuria and lower urinary tract symptoms (LUTS). Initial evaluation revealed a prostate-specific antigen (PSA) level of 11.01 ng/mL, and multiparametric MRI demonstrated locally advanced disease. A transrectal ultrasound (TRUS)-guided biopsy confirmed adenocarcinoma with a Gleason score of 10. Whole-body gallium-68 (⁶⁸Ga) prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET-CT) identified a PSMA-avid prostatic lesion with extension into the seminal vesicles and bladder, along with two focal PSMA-avid deposits in the left testis. Bilateral orchidectomy was performed, and histopathological evaluation confirmed metastatic prostate adenocarcinoma within the left testis. The confirmation of distant metastatic involvement prompted the intensification of systemic therapy with abiraterone and prednisolone, resulting in a decline in PSA to 4.63 ng/mL at four-month follow-up. This case highlights the importance of comprehensive staging in high-grade prostate cancer and demonstrates the clinical utility of PSMA PET-CT in detecting atypical metastatic sites such as the testes, thereby guiding appropriate surgical and systemic treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.